Corrigendum: Research advances in drug therapy of endometriosis

Front Pharmacol. 2023 Jul 14:14:1254518. doi: 10.3389/fphar.2023.1254518. eCollection 2023.

Jianyou Shi^{1

2}, Xin Tan^{1

2}, Guimei Feng^{3

4}, Yuan Zhuo⁵, Zhongliang Jiang⁶, Srikanth Banda⁷, Lin Wang⁸, Wei Zheng⁵, Lu Chen^{1

2}, Dongke Yu^{1

2}, Chun Guo^{3

4}

¹ Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
² Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
³ Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
⁴ Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
⁵ Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
⁶ Miller School of Medicine, University of Miami, Miami, FL, United States.
⁷ Department of Chemistry and Biochemisty, Florida International University, Miami, FL, United States.
⁸ College of Food and Bioengineering, Xihua University, Chengdu, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2023.1199010.].

Keywords: aromatase inhibitor; endometriosis; gonadotropin-releasing antagonist; medical treatment; pathogenesis.